hVIVO #HVO – Trading update – Record H1 revenue and EBITDA margin July 17, 2024 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, provides a trading update for the six-month period ended 30 June 2024.  Highlights • Revenue of £35.6 million, 30.6% higher than H1 2023 (£27.3 million). The Board remains confident in delivering on market expectations for the full year • EBITDA margin of c.24% (H1 2023: 19.1%) •…

Continue reading